Full-Time
Integrated health system delivering patient-centered care
No salary listed
Houston, TX, USA
In Person
Bachelor's, Master's
See people who can refer or advise you
Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.
Company Size
10,001+
Company Stage
Grant
Total Funding
$5M
Headquarters
Houston, Texas
Founded
1907
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Wellness Program
Mental Health Support
Former Houston transplant surgeon's federal case moves toward trial. By Megan Reyna - KHOU 11 Aug 19, 2026 Preview this article 1 min Dr. John Stevenson Bynon, 66, the former surgical director of liver transplantation at Memorial Hermann, is accused of falsifying medical records. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4
Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...
Nebraska Medicine and Memorial Hermann Health System have launched Helix Genomic Advantage, integrating clinical-grade genomic insights into care delivery for their workforces. The programme follows a similar launch with St. Luke's University Health Network. Both health systems are Helix Research Network partners operating large-scale community genomics studies. The Genomic Advantage model aims to implement precision medicine for targeted populations whilst reducing costs, addressing the high expense that has historically prevented scaling diagnostic genomics. "The high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, Helix CEO and co-founder. The programme aligns incentives to drive expanded access and total cost of care reduction across risk-based populations.
Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know